






BMJ Open Prostate-specific membrane antigen positron emission tomography compared to multiparametric MRI for prostate cancer diagnosis: a protocol for a systematic review and meta-analysis

Yi Zhao ¹, Naomi Morka ², Benjamin Scott S Simpson ³, Alex Freeman,⁴ Alex Kirkham,⁵ Daniel Kelly ⁶, Hayley C Whitaker,⁷ Mark Emberton,^{8,9} Joseph M Norris ³

To cite: Zhao Y, Morka N, Simpson BSS, *et al.* Prostate-specific membrane antigen positron emission tomography compared to multiparametric MRI for prostate cancer diagnosis: a protocol for a systematic review and meta-analysis. *BMJ Open* 2021;**11**:e052277. doi:10.1136/bmjopen-2021-052277

► Prepublication history for this paper is available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2021-052277>).

ME and JMN are joint senior authors.

Received 14 April 2021
Accepted 11 November 2021



© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Yi Zhao;
yi.zhao18@imperial.ac.uk

ABSTRACT

Introduction The introduction of multiparametric MRI (mpMRI) has improved almost every aspect of the prostate cancer diagnostic pathway. However, the novel imaging technique, prostate-specific membrane antigen positron emission tomography (PSMA PET) may have demonstrable accuracy in detecting and staging prostate cancer. Here, we describe a protocol for a systematic review and meta-analysis comparing mpMRI to PSMA PET for the diagnosis of suspected prostate cancer.

Methods and analysis A systematic search of MEDLINE, EMBASE, PubMed and Cochrane databases will be conducted. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines will be followed for screening, data extraction, statistical analysis and reporting. Included papers will be full-text articles providing original data, written in English articles and comparing the use of PSMA PET with mpMRI in the diagnosis of prostate cancer. All studies published between July 1977 and March 2021 will be eligible for inclusion. Study bias and quality will be assessed using Quadas-2 score. To ensure the quality of the reporting of studies, this protocol is written following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols 2015 checklist.

Ethics and dissemination Ethical approval will not be required for this systematic review. Findings will be disseminated through peer-reviewed publications and presentations at both national and international conferences.

PROSPERO registration number CRD42021239296.

BACKGROUND

Multiparametric MRI (mpMRI) is now routinely used in the prebiopsy risk stratification of suspected prostate cancer, affording significantly improved diagnostic accuracy over traditional techniques.^{1,2}

However, approximately 10%–20% of clinically significant prostate tumours may be overlooked when using mpMRI,^{3,4} and as

Strengths and limitations of this study

- This will be the first comprehensive systematic review and meta-analysis of the use of prostate-specific membrane antigen positron emission tomography (PSMA PET) and multiparametric MRI in the detection of prostate cancer, written in line with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
- This study will use comprehensive statistical methods to minimise the effect of heterogeneity in the literature on the determined results.
- The heterogeneity of study cohorts may limit the strength of conclusions drawn.
- There is likely to be a less extensive analysis of this focus due to the limited number of studies focusing on the primary diagnosis.
- Due to the recent introduction of PSMA PET as a mean of primary diagnosis, there may be limited long-term data on the clinical outcomes associated with this technology.

a result, the search for a more specific and sensitive imaging modality continues.

Prostate-specific membrane antigen positron emission tomography (PSMA PET) has primarily been used as a staging tool for established prostate cancer, however, there has been a recent surge in interest in using PSMA PET for diagnosis.⁵ PSMA PET enables radionuclide imaging of PSMA, a type II transmembrane glycoprotein, overexpressed in the vast majority of prostate tumours,^{6,7} and is known to correlate with high serum levels of prostate-specific antigen and a higher Gleason score, potentially making this a more targeted and specific marker of prostate cancer.⁸ Conventionally, 68Ga-PSMA PET is coupled with either CT imaging or MRI,⁸

however, alternative radionuclides including, fluorine-18, have been proposed to improve imaging quality by overcoming the limitations exhibited when using the ^{68}Ga radionuclides.⁹

Early PSMA PET diagnostic evaluation studies have shown promising results in the diagnosis of prostate cancer, particularly when compared with the current gold standard imaging approach, mpMRI. It is time to collate the growing evidence in this field, comparing the characteristics of these two imaging modalities, which has not been seen in the existing literature. Currently, existing literature focused on the diagnostic performance of PSMA PET and mpMRI in investigating the recurrence and metastasis of prostate cancer.^{10 11} Other studies have focused on the individual diagnostic performance of either PSMA PET or mpMRI.¹²

This systematic review aims to analyse and summarise the diagnostic accuracies of PSMA PET and mpMRI for the first time, to potentially elucidate whether an alternative but reliable imaging modality can be determined for the detection of prostate cancer.

METHODS AND ANALYSIS

This planned systematic review protocol is written in line with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols 2015 checklist.¹³ Included studies will undergo analysis and thematic synthesis to derive statistical data comparing the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) between PSMA PET and mpMRI. The pooled sensitivities and specificities across the studies will be calculated first before deriving PPV and NPV values.

Search methodology

A systematic search will be carried out using the MEDLINE, PubMed, EMBASE and Cochrane databases to retrieve all studies that contribute relevant evidence. The search will include Medical Subject Heading (MESH) terms and free text with appropriate Boolean operators. The following terms will be included in the search: “prostate”, “cancer”, “diagnosis”, as well as multiple synonyms for the term “PSMA PET” and “mpMRI” to account for differences in terminology. All eligible studies published between July 1977 and February 2021 will be uploaded to Rayyan, a semiautomated tool aimed at improving the speed and reporting accuracy of articles during the initial screening process.¹⁴ To identify any missed studies or additional data, a further manual search of references in all included articles will be performed. In the case of absent or ambiguous data, the corresponding authors will be contacted directly for clarification.

Study selection and data extraction

Three researchers will screen eligible studies independently and assess titles and abstracts for relevance. Should an article be considered eligible, the full text will be retrieved for further review of eligibility. Any

Table 1 Data collection items

| Item no. | Data title | Data type |
|----------|---|----------------------|
| 1 | Year of publication | Study characteristic |
| 2 | Study authors | Study characteristic |
| 3 | Study design | Study characteristic |
| 4 | Patient population | Demographics |
| 5 | Number of participants | Demographics |
| 6 | mpMRI scoring scheme used | Methodology |
| 7 | Definition for clinically significant disease | Methodology |
| 8 | Definition for lesion visibility and invisibility | Methodology |
| 9 | Sample processing approach | Methodology |
| 10 | PSMA PET technique and radionuclide used | Methodology |
| 12 | Histopathological reference standard (including prostate biopsy and wholemount radical prostatectomy) | Methodology |
| 11 | Differential quantification of accuracies | Outcome |

mpMRI, multiparametric MRI.

disagreements between reviewers will be discussed until a consensus is reached, or a fourth reviewer will be consulted. All exclusions will be noted for further analysis and the reasons documented in detail to generate the Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram.

Inclusion criteria

To be included in the analysis, studies must compare the diagnostic accuracies between PSMA PET and mpMRI modality for prostate cancer. Comparisons are focused on investigating sensitivities, specificities, PPVs and NPVs.

Exclusion criteria

Correspondence articles, expert opinions, conference abstracts, review articles and case reports will be excluded. Selected studies must be written in the English language. Studies that do not make a direct comparison between PSMA PET and mpMRI, such as those investigating the combined accuracy in the diagnosis, will be excluded. Articles that solely focus on the diagnostic accuracy of PSMA PET or mpMRI alone will also be removed.

Data extraction

All desired data will be collated in a dedicated datasheet. All reviewers will extract data independently.¹⁵ Table 1 summarises the data to be collected.

Endpoints

The primary endpoint will be statistically significant differences in quantitative measurements (eg, sensitivity, specificity, PPV and NPV) determining diagnostic accuracy between PSMA PET and mpMRI. We will focus on

key themes within the literature such as MRI scoring system (eg, Prostate Imaging-Reporting and Data System (PI-RADS), Likert and radiogenomic features) and the criteria used to define lesion visibility (PI-RADS or Likert score thresholds).

Meta-analysis

The pooled quantitative diagnostic accuracy values between PSMA PET and mpMRI will be compared in the meta-analysis. In the first instance, sensitivity and specificity values will be retrieved or calculated. If studies do not provide these values they will be calculated from clinical tables or requested from study authors. In the instance of a substantial proportion of articles using any other metric, these values may also be retrieved and calculated separately. The distribution of untransformed, logit and double-arcsine transformed proportions will be assessed for normality using the Shapiro-Wilk test and density plots. The set of ratios that most resemble a normal distribution will be used for the combined analysis.

Inter-study variation and heterogeneity will be quantified through I^2 and as the true effect size for all studies are unlikely to be identical (due to methodological differences, institutional differences, interpretation differences) a random-effects model will be fitted for estimation and estimated with partial pooling. Once the model is fit, leave-one-out analyses (LOO) and accompanying diagnostic plots will be used to identify influential studies and will be quantified using externally studentised residuals, different in fits values, Cook's distances, covariance ratios, LOO estimates of the amount of heterogeneity, LOO values of the test statistics for heterogeneity, hat values and weights. Each study will be removed one at a time, and the summary proportions will be re-estimated based on the remaining $n-1$ studies. Studies with a statistically significant influence on the fitted model will be removed as outliers and the model re-fitted. Once heterogeneity has been minimised and outliers removed, summary estimates will be compared between PSMA PET and mpMRI. All data analysis and visualisation will be performed via the R statistical environment (V.3.6.1, 2019-07-05) using the 'mada' and 'mvmeta' packages.

Risk of bias in individual studies

The Quadas-2 score will be used to assess bias and quality across the selected studies.¹⁶ The scoring system is split into three main sections: selection, comparability and outcome. Within each section, there are sub-questions that assess the quality of research methodology at the study level. Three reviewers will be independently involved in this process with any disagreements settled by consensus. The outcome of the bias assessment will be used to influence data synthesis by assessing the applicability and reliability of the data produced. Studies may be excluded if found to be of low quality or suggesting high levels of bias. If they are included, appropriate commentaries will follow in the discussion. As this review is focused on the diagnostic accuracies of prostate cancer between

PSMA PET and mpMRI, we will modify non-applicable sections of the scoring systems to reflect the nature of the evidence base and reduce reporting inaccuracy as reported previously.¹⁵

Patient and public involvement

There will be no patient and public involvement in this study.

DISCUSSION

Today, mpMRI is now widely adopted for prebiopsy risk stratification in men with suspected prostate cancer and has been incorporated into national and international prostate cancer guidelines.¹⁷⁻¹⁹ However, the utility of alternative imaging modalities in this setting is under-explored. Through this systematic review, we aim to compare the diagnostic accuracies of a novel imaging technique, PSMA PET, against the new standard-of-care, mpMRI. The summation of evidence in this fledgeling field will aid in clinical and research decision-making when considering pooled accuracy in the diagnosis of primary prostate cancer, so benefitting patient care.

So far, the bulk of clinical evidence for PSMA PET has supported the use of this technique in the staging of prostate cancer. Indeed, PSMA PET/CT has been shown to independently predict treatment response to salvage radiation treatment, while PSMA PET/MRI has demonstrable accuracy in the staging of primary diagnosed prostate cancer.^{20 21} Furthermore, the two most frequently used radionuclides, ⁶⁸Ga or ¹⁸F, have been shown to have similar results in the staging of clinically significant prostate cancer.²² However, only in recent years, has considerable attention been given to the potential benefits of PSMA PET in the diagnosis of suspected prostate cancer.

There may be several limitations in this review. There may be a small number of studies retrieved as the use of PSMA PET is relatively new. Moreover, there may be a small number of centres have access to PSMA PET technology, giving a limited generalisability of our study. The meta-analysis may be affected by the heterogeneity of results reported in each study. The different type of imaging modality used for both PSMA PET and mpMRI may act as confounders for the results.

This systematic review will combine the extant data, comparing the diagnostic performance of PSMA PET and mpMRI in this novel yet growing field, for the first time. The collation and analysis of these data will allow a better understanding of the differences in diagnostic utility between PSMA PET and mpMRI. Additionally, this process will also aid in clinical decision-making for prostate cancer diagnosis as well as potential areas for further research.

Trial status

- ▶ Preliminary searches: started
- ▶ Piloting of the study selection process: started
- ▶ Formal screening: not started



- ▶ Data extraction: not started
- ▶ Risk of bias assessment: not started
- ▶ Data analysis: not started

Draft search strategy

((((Prostat* AND (Cancer OR malignan* OR adenocarcinoma OR lesion* OR Disease)) AND (PSMA OR “prostate-specific membrane antigen positron emission tomography”)) AND (MR OR magnetic resonance imaging OR MP-MRI OR multi-parametric MRI OR multi-parametric magnetic resonance imaging OR multiparametric MRI OR “multiparametric magnetic resonance imaging”))) AND Diagnosis).ti,ab

ETHICS AND DISSEMINATION

Due to the nature of this review, there are no relevant ethical concerns and informed consent will not be required. The protocol and systematic review will be disseminated via a peer-reviewed journal.

Author affiliations

¹Imperial College London, London, UK

²University College London Medical School, London, UK

³UCL Division of Surgery & Interventional Science, University College London, London, UK

⁴Department of Histopathology, University College Hospital London, London, UK

⁵Department of Radiology, University College London Hospitals NHS Foundation Trust, London, UK

⁶School of Healthcare Sciences, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK

⁷UCL Division of Surgery and Interventional Science, University College London, London, UK

⁸Division of Surgery and Interventional Sciences, University College London, London, UK

⁹Department of Urology, University College London Hospital, London, UK

Twitter Naomi Morka @naomi_morka, Benjamin Scott S Simpson @b3nsimp and Joseph M Norris @MrJosephNorris

Contributors The authors' contribution includes, but is not limited to, the following: NM, BSSS and JMN drafted the manuscript and created the study concept. AK, AF, DK, HCW and ME provided supervision and guidance during the study. All authors reviewed and approved the manuscript in its current form. YZ is the guarantor of this work.

Funding JMN is funded by the Medical Research Council (MRC) (MR/S00680X/1). BSSS is funded by the Royal Marsden Cancer Charity. ME receives research support from the UK's National Institute of Health Research (NIHR) UCLH/UCL Biochemical Research Centre.

Competing interests JMN receives funding from the MRC. Simpson receives funding from the Royal Marsden Cancer Charity. HCW receives funding from Prostate Cancer UK, the Urology Foundation and Rosetrees Trust. AK, AF and ME have stock interest in Nuada Medical. ME acts as a consultant, trainer and proctor to Sonatherm; Angiodynamics; Exact Imaging.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

ORCID iDs

Yi Zhao <http://orcid.org/0000-0002-4563-4344>

Naomi Morka <http://orcid.org/0000-0002-1925-7223>

Benjamin Scott S Simpson <http://orcid.org/0000-0003-3685-6110>

Daniel Kelly <http://orcid.org/0000-0002-1847-0655>

Joseph M Norris <http://orcid.org/0000-0003-2294-0303>

REFERENCES

- Ahmed HU, El-Shater Bosaily A, Brown LC, *et al*. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. *Lancet* 2017;389:815–22.
- Kasivisvanathan V, Rannikko AS, Borghi M, *et al*. MRI-Targeted or standard biopsy for prostate-cancer diagnosis. *N Engl J Med* 2018;378:1767–77.
- Bass EJ, Pantovic A, Connor M, *et al*. A systematic review and meta-analysis of the diagnostic accuracy of biparametric prostate MRI for prostate cancer in men at risk. *Prostate Cancer Prostatic Dis* 2021;24:1–16.
- Radtke JP, Kuru TH, Boxler S, *et al*. Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance. *J Urol* 2015;193:87–94.
- Satapathy S, Singh H, Kumar R, *et al*. Diagnostic Accuracy of ⁶⁸Ga-PSMA PET/CT for Initial Detection in Patients With Suspected Prostate Cancer: A Systematic Review and Meta-Analysis. *Am J Roentgenol* 2021;216:599–607.
- Wright GL, Haley C, Beckett ML, *et al*. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. *Urol Oncol* 1995;1:18–28.
- Bouchelouche K, Choyke PL. Advances in PSMA positron emission tomography (PET) of prostate cancer. *Curr Opin Oncol* 2018;30:189–96.
- Hoffmann MA, Wieler HJ, Baues C, *et al*. The impact of ⁶⁸Ga-PSMA PET/CT and PET/MRI on the management of prostate cancer. *Urology* 2019;130:1–12.
- Kesch C, Kratochwil C, Mier W. ⁶⁸Ga or ¹⁸F for prostate cancer imaging? *J Nucl Med* 2017;58:687–8.
- Albisinni S, Aoun F, Marcelis Q, *et al*. Innovations in imaging modalities for recurrent and metastatic prostate cancer: a systematic review. *Minerva Urol Nefrol* 2018;70:347–60.
- De Visschere P, Standaert C, Fütterer JJ, *et al*. A systematic review on the role of imaging in early recurrent prostate cancer. *Eur Urol Oncol* 2019;2:47–76.
- Evangelista L, Zattoni F, Cassarino G, *et al*. PET/MRI in prostate cancer: a systematic review and meta-analysis. *Eur J Nucl Med Mol Imaging* 2021;48:859–73.
- Moher D, Shamseer L, Clarke M, *et al*. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1.
- Ouzzani M, Hammady H, Fedorowicz Z, *et al*. Rayyan-a web and mobile app for systematic reviews. *Syst Rev* 2016;5:210.
- Genetic landscape of prostate cancer conspicuity on multiparametric MRI: a protocol for a systematic review and bioinformatic analysis | BMJ open. Available: <https://bmjopen.bmj.com/content/10/1/e034611.abstract> [Accessed 1 Mar 2021].
- Whiting PF, Rutjes AWS, Westwood ME, *et al*. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med* 2011;155:529–36.
- Jones R, Cornford P. EAU and NICE guidelines for the diagnosis and management of prostate cancer. How wide is the channel? *Journal of Clinical Urology* 2018;11:149–53.
- Dasgupta P, Davis J, Hughes S. NICE guidelines on prostate cancer 2019. *BJU Int* 2019;124:1.
- Wise J. NICE recommends MRI for suspected prostate cancer to reduce biopsies. *BMJ* 2018;363:k5290.
- Emmett L, van Leeuwen PJ, Nandurkar R, *et al*. Treatment Outcomes from ⁶⁸Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET. *J Nucl Med* 2017;58:1972–6.
- Grubmüller B, Baltzer P, Hartenbach S, *et al*. Psma ligand PET/MRI for primary prostate cancer: staging performance and clinical impact. *Clin Cancer Res* 2018;24:6300–7.
- Kuten J, Fahoum I, Savin Z, *et al*. Head-to-Head Comparison of ⁶⁸Ga-PSMA-11 with ¹⁸F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard. *J Nucl Med* 2020;61:527–32.